Background
Methods
Study sample
Clinical assessment and laboratory biomarkers
Imaging assessment
Statistical analysis
Results
Patient characteristics
HCs | TA (N = 42) |
p value | |
---|---|---|---|
Qualitative variables | |||
Sex (F:M) | 20:0 | 39:3 | n.s. |
Class of arterial involvement: | N.E. | ||
1 2A 2B 3 4 5 | - - - - - - | 4 (10 %) 4 (10 %) 3 (7 %) 1 (2 %) 0 30 (71 %) | - - - - - - |
Coronary involvement | N.E. | 6 (14 %) | - |
Pulmonary artery involvement | N.E. | 13 (31 %) | - |
Aneurysms | 0 | 16 (38 %) | - |
Steroids | 0 | 30 (71 %) | - |
Immunosuppressive therapy: Azathioprine Methotrexate Mycophenolate Sirolimus Cyclophosphamide | 0 - - - - - | 30 (71 %) 12 (29 %) 11 (26 %) 4 (10 %) 2 (5 %) 1 (2 %) | - - - - - - |
Biologic therapy: TNF blockers Tocilizumab Rituximab | 0 - - - | 19 (45 %) 16 (38 %) 2 (5 %) 1 (2 %) | - - - - |
Active disease (NIH criteria) | N.E. | 12 (29 %) | - |
Anticoagulants | 0 | 7 (17 %) | - |
Arterial hypertension | 0 | 22 (52 %) | - |
Cardiac involvement | N.E. | 12 (29 %) | - |
Vascular enhancement (N = 30) | N.E. | 5 (16 %) | - |
Vascular progression (N = 40) | N.E. | 9 (22 %) | - |
Scalar variables (median, range) | |||
Age at disease onset (years) | N.E. | 30 (17–56) | - |
Disease duration (years) | N.E. | 10 (0-34) | - |
Creatinine (mg/dl) | N.A. | 0.70 (0.44–1.60) | - |
PDN dose (mg/day; N = 30) | 0 | 5 (3–35) | - |
N vessels | N.E. | 4 (1–7) | - |
ESR (mm/h) | N.A. | 15 (1–78) | - |
Serum CRP (mg/l) | 0.6 (0.3–9.0) | 2.6 (0.03–40) | 0.017 |
Plasma PTX3 (ng/ml) | 3.9 (1.4–6.5) | 5.5 (1.3–55) | 0.009 |
CgAtot (nM) | 0.98 (0.47–1.72) | 2.36 (0.45–7.85) | 0.001 |
CgA439 (nM) | 0.04 (0–0.07) | 0.05 (0-0–.78) | n.s. |
CgA-FRs (nM) | 0.64 (0.22–1.17) | 1.63 (0.22–6.68) | 0.001 |
VS-1 (nM) | 0.10 (0.07–0.50) | 0.20 (0.02–1.15) | 0.020 |
CgA439/CgAtot
| 5 % (0–17 %) | 1 % (0–24 %) | n.s. |
CgA-FRs/CgAtot
| 67 % (46–88 %) | 66 % (47–94 %) | n.s. |
VS-1/CgAtot
| 13 % (7–29 %) | 11 % (1–27 %) | n.s. |
CgA levels in TA
Therapy with PPIs | Arterial hypertension | |||||
---|---|---|---|---|---|---|
No (N = 12) | Yes (N = 30) |
p value | No (N = 20) | Yes (N = 22) |
p value | |
Qualitative variables | ||||||
Sex (F:M) | 11:1 | 28:2 | n.s. | 20:0 | 19:3 | n.s. |
Class of arterial involvement: | ||||||
1 2A 2B 3 4 5 | 1 2 1 0 0 8 | 3 2 2 1 0 22 | n.s. n.s. n.s. n.s. N.A. n.s. | 2 3 1 1 0 13 | 2 1 2 0 0 17 | n.s. n.s. n.s. n.s. N.A. n.s. |
Aneurysms | 6 | 10 | n.s. | 7 | 9 | n.s. |
Steroids | 3 | 27 | <0.001 | 13 | 17 | n.s. |
Immunosuppressive therapy: | 7 | 23 | n.s. | 11 | 19 | 0.04 |
Biologic therapy: TNF blockers Tocilizumab | 4 3 1 | 15 13 1 | n.s. n.s. n.s. | 10 9 1 | 9 7 1 | n.s. n.s. n.s. |
Active disease (NIH criteria) | 0 | 12 | 0.009 | 5 | 6 | n.s. |
Anticoagulants | 3 | 4 | n.s. | 3 | 4 | n.s. |
Arterial hypertension | 4 | 18 | n.s. | N.E. | N.E. | |
Therapy with PPIs | N.E. | N.E. | ||||
Cardiac involvement | 4 | 8 | n.s. | 6 | 6 | n.s. |
Vascular enhancement (N = 30) | 1 | 4 | n.s. | 3 | 2 | n.s. |
Vascular progression (N = 40) | 1 | 8 | n.s. | 5 | 4 | n.s. |
Scalar variables (median and range) | ||||||
Age (years) | 51 (31–66) | 41 (23–62) | 0.060 | 40 (23–66) | 47 (26–65) | n.s. |
Age at TA onset (years) | 36 (21–56) | 28 (17–56) | n.s. | 29 (17–56) | 30 (18–56) | n.s. |
Disease duration (years) | 12 (4–21) | 9 (0–34) | n.s. | 9 (2–21) | 11 (0–34) | n.s. |
Creatinine (mg/dl) | 0.70 (0.44–1.06) | 0.70 (0.56–1.60) | n.s. | 0.67 (0.49–0.89) | 0.75 (0.44–1.61) | 0.084 |
PDN dose (mg/day) | 0 (0–12.5) | 5 (0–35) | <0.001 | 5 (0–25) | 5 (0–35) | n.s. |
N vessels | 4 (1–6) | 4 (1–7) | n.s. | 3 (1–-6) | 4 (1–7) | n.s. |
ESR (mm/h) | 9 (1–23) | 18 (2–78) | 0.059 | 13 (2–73) | 18 (1–78) | n.s. |
Serum CRP (mg/l) | 1.5 (0.1–12) | 3.0 (0.3–40) | 0.104 | 2.0 (0.1-40) | 2.6 (0.3–36.8) | n.s. |
Plasma PTX3 (ng/ml) | 4.1 (1.3–44) | 5.9 (2.2–55) | n.s. | 5.8 (2.5–43.6) | 5.3 (1.3–55.0) | n.s. |
CgAtot (nM) | 1.02 (0.45–2.66) | 3.40 (0.60–7.85) | <0.001 | 1.35 (0.5–3-6.31) | 3.76 (0.45–7.85) | 0.021 |
CgA439 (nM) | 0 (0-0–19) | 0.07 (0–0.78) | n.s. | 0.01 (0–0.44) | 0.07 (0–0.78) | n.s. |
CgA-FRs (nM) | 0.76 (0.22–1.82) | 2.18 (0.28–6.68) | <0.001 | 0.89 (0.39–3.93) | 2.45 (0.22–6.68) | 0.030 |
VS-1 (nM) | 0.10 (0.02–0.34) | 0.25 (0.06–1.15) | 0.001 | 0.11 (0.02–0.79) | 0.32 (0.05–1.15) | 0.024 |
CgA439/CgAtot
| 0 % (0–18 %) | 2 % (0–24 %) | n.s. | 0 % (0–18 %) | 2 % (0–24 %) | n.s. |
CgA-FRs/CgAtot
| 69 % (50–84 %) | 66 % (47–94 %) | n.s. | 69 % (50–84 %) | 66 % (47–94 %) | n.s. |
VS-1/CgAtot
| 12 % (1–24 %) | 10 % (3–27 %) | n.s. | 12 % (1–24 %) | 10 % (3–27 %) | n.s. |
Rank CgA439+ rank VS-1 | 27 (5–50) | 41 (18–83) | 0.002 | 32 (5–64) | 44 (8–83) | 0.023 |
Arterial hypertension is associated with higher CgA-FRs and VS-1 in TA
CgA439, CgA-FRs and VS-1 differentially reflect systemic and local inflammation in normotensive and hypertensive TA patients
Whole TA group (N = 42) | ||||
CgA439
| CgA-FRs | VS-1 | CgAtot
| |
ESR | 0.179 n.s. | 0.181 n.s. | 0.173 n.s. | 0.158 n.s. |
CRP | 0.015 n.s. | 0.326
p = 0.035 | 0.229 n.s. | 0.300
p = 0.053 |
PTX3 | -0.232 n.s. | -0.082 n.s. | 0.291
p = 0.062 | 0.085 n.s. |
N vessels | 0.196 n.s. | 0.039 n.s. | -0.047 n.s. | 0.066 n.s. |
CgA439/CgAtot
| CgA-FRs/CgAtot
| VS-1/CgAtot
| ||
ESR | 0.134 n.s. | 0.178 n.s. | 0.016 n.s. | |
CRP | -0.009 n.s. | 0.088 n.s. | -0.123 n.s. | |
PTX3 | -0.022 n.s. | -0.123 n.s. | 0.154 n.s. | |
N vessels | 0.153 n.s. | -0.176 n.s. | -0.178 n.s. | |
TA on PPIs (N = 30) | ||||
CgA439
| CgA-FRs | VS-1 | CgAtot
| |
ESR | 0.119 n.s. | 0.045 n.s. | 0.010 n.s. | 0.002 n.s. |
CRP | 0.030 n.s. | 0.140 n.s. | 0.028 n.s. | 0.142 n.s. |
PTX3 | -0.258 n.s. | 0.065 n.s. | 0.176 n.s. | 0.071 n.s. |
N vessels | 0.309
p = 0.096 | 0.017 n.s. | -0.009 n.s. | 0.076 n.s. |
CgA439/CgAtot
| CgA-FRs/CgAtot
| VS-1/CgAtot
| ||
ESR | 0.174 n.s. | 0.319
p = 0.097 | -0.009 n.s. | |
CRP | 0.106 n.s. | 0.200 n.s. | -0.169 n.s. | |
PTX3 | -0.241 n.s. | 0.037 n.s. | 0.133 n.s. | |
N vessels | 0.251 n.s. | -0.194 n.s. | -0.138 n.s. | |
Normotensive TA (N = 20) | ||||
CgA439
| CgA-FRs | VS-1 | CgAtot
| |
ESR | -0.368 n.s. | -0.028 n.s. | 0.415
p = 0.110 | -0.162 n.s. |
CRP | -0.124 n.s. | 0.389
p = 0.090 | 0.576
p = 0.008 | 0.346 n.s. |
PTX3 | -0.422
p = 0.061 | 0.030 n.s. | 0.386
p = 0.093 | -0.003 n.s. |
N vessels | -0.074 n.s. | 0.088 n.s. | 0.029 n.s. | 0.082 n.s. |
CgA439/CgAtot
| CgA-FRs/CgAtot
| VS-1/CgAtot
| ||
ESR | -0.168 n.s. | 0.570
p = 0.021 | 0.684
p = 0.003 | |
CRP | -0.036 n.s. | 0.254 n.s. | -0.309 n.s. | |
PTX3 | -0.435
p = 0.055 | 0.159 n.s. | 0.480
p = 0.032 | |
N vessels | 0.072 n.s. | -0.012 n.s. | -0.057 n.s. | |
Hypertensive TA (N = 22) | ||||
CgA439
| CgA-FRs | VS-1 | CgAtot
| |
ESR | 0.517
p = 0.020 | 0.295 n.s. | -0.192 n.s. | 0.276 n.s. |
CRP | 0.149 n.s. | 0.347 n.s. | 0.049 n.s. | 0.324 n.s. |
PTX3 | -0.030 n.s. | 0.157 n.s. | 0.088 n.s. | 0.153 n.s. |
N vessels | 0.382
p = 0.076 | -0.222 n.s. | -0.259 n.s. | -0.104 n.s. |
CgA439/CgAtot
| CgA-FRs/CgAtot
| VS-1/CgAtot
| ||
ESR | 0.536
p = 0.015 | -0.085 n.s. | -0.561
p = 0.010 | |
CRP | 0.134 n.s. | 0.136 n.s. | -0.455
p = 0.033 | |
PTX3 | -0.052 n.s. | -0.082 n.s. | -0.010 n.s. | |
N vessels | 0.389
p = 0.073 | -0.203 n.s. | -0.311 n.s. |
CgA439, CgA-FRs and VS-1 levels do not reflect disease activity, extent or progression
Whole TA sample | No arterial wall enhancement (N = 25) | Arterial wall enhancement (N = 5) |
p value |
CgA439 (nM) | 0.06 (0–0.62) | 0.00 (0–0.78) | n.s. |
CgA-FRs (nM) | 1.85 (0.39–5.03) | 1.41 (0.32–3.93) | n.s. |
VS-1 (nM) | 0.25 (0.02–1.15) | 0.23 (0.10–0.79) | n.s. |
Rank CgA439 + rank VS-1 | 38 (5–83) | 36 (24–80) | n.s. |
Patients on PPIs | No arterial wall enhancement (N = 20) | Arterial wall enhancement (N = 4) |
p value |
CgA439 (nM) | 0.07 (0–0.62) | 0.00 (0–0.78) | n.s. |
CgA-FRs (nM) | 2.45 (0.41–5.03) | 2.60 (1.25–3.93) | n.s. |
VS-1 (nM) | 0.27 (0.06-1.15) | 0.48 (0.22–0.79) | n.s. |
Rank CgA439 + rank VS-1 | 44 (29–83) | 32 (24–80) | n.s. |
Hypertensive patients | No arterial wall enhancement (N = 13) | Arterial wall enhancement (N = 2) |
p value |
CgA439 (nM) | 0.06 (0–0.62) | 0.43 (0.09–0.78) | n.s. |
CgA-FRs (nM) | 2.76 (0.77–5.03) | 2.06 (0.32–3.8) | n.s. |
VS-1 (nM) | 0.38 (0.17–1.15) | 0.42 (0.10–0.74) | n.s. |
Rank CgA439 + rank VS-1 | 50 (28–83) | 58 (36–80) | n.s. |
Whole TA sample | Inactive TA (N = 30) | Active TA (N = 12) |
p value |
CgA439 (nM) | 0.05 (0–0.62) | 0.03 (0–0.78) | n.s. |
CgA-FRs (nM) | 1.37 (0.22–6.68) | 1.80 (0.28–5.03) | n.s. |
VS-1 (nM) | 0.19 (0.02–1.15) | 0.21 (0.09–0.79) | n.s. |
Rank CgA439 + rank VS-1 | 37 (5–83) | 35 (18–80) | n.s. |
Patients on PPIs | Inactive TA (N = 18) | Active TA (N = 12) |
p value |
CgA439 (nM) | 0.08 (0–0.62) | 0.03 (0–0.78) | n.s. |
CgA-FRs (nM) | 2.55 (0.41–6.68) | 1.80 (0.28–5.03) | n.s. |
VS-1 (nM) | 0.32 (0.06–1.15) | 0.21 (0.09–0.79) | n.s. |
Rank CgA439 + rank VS-1 | 52 (24–83) | 35 (18–80) | 0.072 |
Hypertensive patients | Inactive TA (N = 15) | Active TA (N = 7) |
p value |
CgA439 (nM) | 0.08 (0–0.62) | 0.06 (0–0.78) | n.s. |
CgA-FRs (nM) | 2.50 (0.22–6.68) | 1.85 (0.28–5.03) | n.s. |
VS-1 (nM) | 0.39 (0.05–1.15) | 0.20 (0.09–0.74) | n.s. |
Rank CgA439 + rank VS-1 | 50 (8–83) | 39 (18–80) | n.s. |
Whole TA sample | No vascular progression (N = 31) | Vascular progression (N = 9) |
p value |
CgA439 (nM) | 0.06 (0–0.78) | 0 (0–0.14) | n.s. |
CgA-FRs (nM) | 1.49 (0.22–5.03) | 1.76 (0.32–4.24) | n.s. |
VS-1 (nM) | 0.20 (0.02–1.15) | 0.20 (0.09–0.79) | n.s. |
Rank CgA439+ rank VS-1 | 42 (5–83) | 36 (22–40) | n.s. |
Patients on PPIs | No vascular progression (N = 20) | Vascular progression (N = 8) |
p value |
CgA439 (nM) | 0.09 (0–0.78) | 0 (0–0.14) | 0.063 |
CgA-FRs (nM) | 2.45 (0.41–5.03) | 1.81 (0.46–4.24) | n.s. |
VS-1 (nM) | 0.27 (0.06–1.15) | 0.21 (0.09–0.79) | n.s. |
Rank CgA439 + rank VS-1 | 52 (24–83) | 34.5 (22–40) | 0.010 |
Hypertensive patients | No vascular progression (N = 16) | Vascular progression (N = 4) |
p value |
CgA439 (nM) | 0.08 (0–0.78) | 0.05 (0–0.14) | n.s. |
CgA-FRs (nM) | 2.63 (0.22–5.03) | 1.40 (0.32–4.24) | n.s. |
VS-1 (nM) | 0.39 (0.05–1.15) | 0.15 (0.09–0.37) | n.s. |
Rank CgA439 + rank VS-1 | 52 (8–83) | 33 (22–39) | 0.050 |